Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies mig...

Descripción completa

Detalles Bibliográficos
Autores principales: Wurm, Hannah, Attfield, Kate, Iversen, Astrid KN, Gold, Ralf, Fugger, Lars, Haghikia, Aiden
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report and Clinical Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502978/
https://www.ncbi.nlm.nih.gov/pubmed/32762494
http://dx.doi.org/10.1177/1352458520943791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502978/
https://www.ncbi.nlm.nih.gov/pubmed/32762494
http://dx.doi.org/10.1177/1352458520943791

Ejemplares similares